Oslo University Hospital has awarded 6 excellent articles for the first half-year of 2012

Oslo University Hospital has now rewarded six research groups for their excellent papers published during the first half-year of 2012. Each group receives NOK 50.000 for use in further research. The prizes were distributed during the staff meeting at Rikshospitalet Friday October 26th.

In order to stimulate excellent research and draw attention to the hospital's extensive research activity, Oslo University Hospital reward outstanding publications regularly. Every half-year, six of the very best papers authored by scientists working on the hospital (first or last author must be affiliated to OUS) are selected. The nomination takes place through the research panel of each division. The final selection process is performed by an external committee.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital, which the hospital is very proud of. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment, says the director for research, innovation and education, Erlend B. Smeland.

The articles are nominated by the research panels in the hospitals respective clinics. Then they have been evaluated by an external committee, who have selected six winners. The leader of the committee was Sigbjørn Fossum from the Faculty of Medicine, Institute of Basic Medical Sciences.

The six articles awarded as winners for the first half-year of 2012 are here presented alphabetically after first author:

Centre for Immune Regulation, Department of Immunology, Division of Diagnostics and Intervention

 

High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions.
Di Niro R, Mesin L, Zheng NY, Stamnaes J, Morrissey M, Lee JH, Huang M, Iversen R, du Pré MF, Qiao SW, Lundin KE, Wilson PC, Sollid LM.
Nat Med. 2012 Feb 26;18(3):441-5. doi: 10.1038/nm.2656.

PMID: 22366952 Link to abstract from PubMed

Institute for Cancer Research, Division of Cancer Medicine, Surgery and Transplantation

The gap junction channel protein connexin 43 is covalently modified and regulated by SUMOylation.
Kjenseth A, Fykerud TA, Sirnes S, Bruun J, Yohannes Z, Kolberg M, Omori Y, Rivedal E, Leithe E.
J Biol Chem. 2012 May 4;287(19):15851-61. Epub 2012 Mar 12.

PMID: 22411987 Link to abstract from PubMed

Department of Medical Biochemistry, Division of Diagnostics and Intervention

The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E, Grudic A, Pankiv S, Bruserud O, Simonsen A, Bjerkvig R, Bjørås M, Bøe SO.
Blood. 2012 Jul 26;120(4):847-57. Epub 2012 Jun 12.

PMID: 22692509 Link to abstract from PubMed

National Resource Center for Late Effects after Cancer Treatment, Department of Oncology, Division of Cancer Medicine, Surgery and Transplantation

Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.
Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, Beard C, Haugnes HS, Fosså SD, Oldenburg J, Travis LB.
J Clin Oncol. 2012 Jan 20;30(3):300-7. Epub 2011 Dec 19.

PMID: 22184390 Link to abstract from PubMed

Institute for Experimental Medical Research, Division of Cardiovascular and Pulmonary Diseases

Extreme sarcoplasmic reticulum volume loss and compensatory T-tubule remodeling after Serca2 knockout.
Swift F, Franzini-Armstrong C, Øyehaug L, Enger UH, Andersson KB, Christensen G, Sejersted OM, Louch WE.
Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3997-4001. Epub 2012 Feb 21.

PMID: 22355118 Link til article in full text format

Department of Oncology, Division of Cancer Medicine, Surgery and Transplantation

Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T.
J Clin Oncol. 2012 May 20;30(15):1755-62. Epub 2012 Apr 2.

PMID: 22473155 Link to abstract from PubMed

Prize winners after the ceremony October 26th. From left: Kjell Magne Tveit, Fredrik Swift, Mette Sprauten, Stig Ove Bøe, Ane Kjenseth, Luka Mesin. (Photo: Ram Gupta, OUS) (click to enlarge image)

Links:

News article about the article award from the home page of Oslo University Hospital (in Norwegian):
Fremragende forskningsartikler får pris
This article contains summaries of the findings in each of the six award-winning papers

Publication lists of first authors (from ous-research.no)

Kjell Magne Tveit

Fredrik Swift

Mette Sprauten

Stig Ove Bøe

Ane Kjenseth

Luka Mesin

Home pages of research groups:

Department of Oncology (Tveit)

Institute for Experimental Medical Research (Swift)

National Resource Center for Late Effects after Cancer Treatment (Sprauten)

Stig Ove Bøe's group (Bøe)

Edgar Rivedahl's group (Kjenseth)

Ludvig Sollid's group (Mesin)

 
Page visits: 6187